Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

544 ARTÍCULOS , VIENDO DEL 511 AL 525

Lost in Space and Thought: Navigating the Cognitive Map in Alzheimer's Disease

Zhao B, Zhou S, Wei T, Xu J, Geng C, Wang Z, Tang Y.

Neurosci Bull. 2026 Mar;42(3):697-711. doi: 10.1007/s12264-025-01541-x. Epub 2025 Nov 7.

Comparative efficacy and safety of different brexpiprazole doses for agitation in Alzheimer's disease: A systematic review and network meta-analysis

Kandeel M, Mahmoud M.

J Alzheimers Dis. 2026 Feb;109(3):1089-1098. doi: 10.1177/13872877251404500. Epub 2025 Dec 8.

Cognitive adaptations for memory deficits in MCI and AD patients: A meta-analysis of EEG microstates

Piton T, Smailovic U, Jelic V, Koenig T, Unschuld PG, Bréchet L.

Neuroimage Clin. 2026;49:103929. doi: 10.1016/j.nicl.2025.103929. Epub 2025 Dec 24.

Speech pause and speech rate for evaluating Alzheimer's and mild cognitive impairment: A meta-analysis

Cohen AS, Divers R, Calamia M, Masucci M, Granrud OE, Corporandy A, Warren KK, Elvevåg B, Chandler C, Diaz-Asper C.

J Int Neuropsychol Soc. 2026 Jan;32(1):24-31. doi: 10.1017/S1355617725101677. Epub 2025 Dec 11.

Efficacy and Safety of Escitalopram and Citalopram for Agitation in Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

da Silva AMP, Falcão L, Virgilio Ribeiro F, Ogasawara Donato K, Machado Magalhães PL, Nascimento MDVS, Leite M, Lee Han M, Quiroga DG, de Souza Franco E, de Sousa Maia MB.

J Geriatr Psychiatry Neurol. 2026 May;39(3):249-260. doi: 10.1177/08919887251369893. Epub 2025 Aug 22.

Task-based fMRI brain activation in mild cognitive impairment and Alzheimer's disease: an ALE meta-analysis

Lee ZL, Li JJ, Siew SKH, Billaud CHA, Yu J.

Geroscience. 2026 Apr;48(2):3069-3096. doi: 10.1007/s11357-025-01850-z. Epub 2025 Aug 29.

IL-24 ameliorates cognitive dysfunction via the inhibition PERK-eIF2α Signaling pathway in Alzheimer's disease

Du Y, Zheng X, Yue X, Fu P, Diao J, Zhang A, Cheng H, Yang H, Bi J, Zhou Q, Wang P.

Int Immunopharmacol. 2026 Jan 15;169:116039. doi: 10.1016/j.intimp.2025.116039. Epub 2025 Dec 18.

Mind Your Mouth: Impact of Oral Bacteria on Alzheimer's Disease

Mohammed AI, Mohammed AI, Reynolds E.

J Oral Pathol Med. 2026 Jan;55(1):1-6. doi: 10.1111/jop.70111. Epub 2025 Dec 23.

A Randomized Controlled Trial of the Safety and Efficacy of Dronabinol for Agitation in Alzheimer's Disease

Rosenberg PB, Amjad H, Burhanullah H, Nowrangi M, Vandrey R, Pierre MJ, Outen JD, Schultz M, Marano C, Agronin M, Wilkins JM, Harper D, Laffaye T, Reardon E, Turner K, Ozonsi R, Drury M, Nguyen A, Hasoğlu T, Cromwell J, Leoutsakos JM, Forester BP.

Am J Geriatr Psychiatry. 2026 Feb;34(2):167-179. doi: 10.1016/j.jagp.2025.10.011. Epub 2025 Nov 10.

Zinc transporter proteins in the retina as potential biomarkers for staging early Alzheimer's disease: Comparative analysis in human and mouse models

Mashkani SMH, Bishop D, Adlard PA, Mojtaba Golzan S.

Neurobiol Aging. 2026 Jan;157:26-35. doi: 10.1016/j.neurobiolaging.2025.09.010. Epub 2025 Oct 1.

Reconciling recommendations for ethical sharing of biomarker results with Alzheimer's disease research participants: A systematic review and qualitative synthesis

Webster H, Zelinsky M, Rico V, Martinez K, Sankary L.

J Alzheimers Dis. 2026 Mar;110(1):46-57. doi: 10.1177/13872877251392555. Epub 2025 Nov 5.

Association of neighborhood disadvantage with Alzheimer's disease pathology and the stability of blood-based biomarker performance

Myoraku A, Hausle I, Mila-Aloma M, Thropp P, Wang LA, Doraiswamy PM, Tosun D; Alzheimer’s Disease Neuroimaging Initiative*.

J Prev Alzheimers Dis. 2026 Feb;13(2):100445. doi: 10.1016/j.tjpad.2025.100445. Epub 2025 Nov 23.

Amyloid Clearance and Transient CSF Aβ40 Reduction in a Case of ARIA-E/H Following Lecanemab Treatment

Naeshiro Y, Kitani-Morii F, Kasai T, Tanaka E, Kobayashi F, Ohara T.

Intern Med. 2026 Apr 1;65(7):1056-1060. doi: 10.2169/internalmedicine.6070-25. Epub 2025 Aug 21.

Identifying a combination of biomarkers to predict treatment response to nabilone for agitation in Alzheimer's disease - an exploratory post hoc analysis

Wang HJ, Ruthirakuhan M, Andreazza AC, Beroncal EL, Black SE, Gallagher D, Herrmann N, Kiss A, Verhoeff NPLG, Lanctôt KL.

Neurodegener Dis Manag. 2026 Apr-Jun;16(3):263-272. doi: 10.1080/17582024.2025.2587549. Epub 2025 Nov 11.

Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer's Disease: Synthesis of Evidence from Observational and Interventional Trials

Abushakra S, Doraiswamy PM, Hey JA, Tosun D, Barkhof F, Barakos J, Petrella J, Kesslak JP, Power A, Sabbagh M, Porsteinsson A, Cohen S, Gauthier S, Ritchie C, Watson D, McSweeney E, Boada M, Liang E, Bracoud L, McLaine R, Flint S, Schaefer JF, Yu J, Bray M, Hendrix S, Dickson S, Durrant A, Albayrak A, Tolar M.

CNS Drugs. 2026 Feb;40(2):199-214. doi: 10.1007/s40263-025-01251-y. Epub 2025 Dec 1.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias